



# **Speed Networking**

## **with STEM Professionals**

Thursday, May 19<sup>th</sup> 2022

Online Platform: Remo

# **Agenda**

<b>5:45 - 6:00PM</b>	Panelist Introductions
<b>6:00 - 7:15PM</b>	Speed Networking
<b>7:15PM - 7:30PM</b>	Optional Networking

# TABLE OF CONTENTS:

Science Communication	4-5
Academic roles	6-7
Industry Research & Development	8-9
Data Science	10-11
Alliance & Project Management	12-13
Non Profit Organizations	14-15
Medical Science Liaison	16-17
Business Development	18

**Srilatha Raghuram** has a Ph.D. in Pharmacology (2008) from the University of Virginia, Charlottesville, and a research background in nuclear receptor biology, structural biology, circadian clock, metabolism, and angiogenesis. After completing her postdoctoral fellowship at Harvard Medical School, she joined Elsevier as a Scientific Editor for the journal *BBRC (Biochemical and Biophysical Research Communications)* for six years (2012- 2018). She then moved on to Mary Ann Liebert Inc. as a Journals Publisher and managed over 30 life sciences journals in that role for three years before joining the Alzheimer's Association in June 2021. She has over nine years of experience in scientific publishing and in her current role manages the three Alzheimer's Association journals, including *Alzheimer's & Dementia* as part of the medical and scientific team working as a liaison between the editors, Wiley, and the Alzheimer's Association. Srilatha is originally from Coimbatore, India.




**Jenny Rood** is the gRED Communications Manager at **Genentech**. Prior to joining Genentech, she spent more than five and a half years at the Broad Institute of MIT and Harvard, working in the development office and then as a direct scientific writing adviser to lead scientists at the institute. She earned a Ph.D. in biology from MIT prior to entering the Graduate Program in Science Writing. Before joining the Broad, Jenny was an intern at the International Center for Theoretical Physics in Trieste, Italy, and an editorial intern at *The Scientist*. Her video and written work has also appeared in *Technology Review*.



**Silvia Velasco** is an Associate Professor and Group Leader of the Neural Stem Cell Laboratory at the **Murdoch Children's Research Institute (MCRI)** and Honorary Senior Fellow in the Department of Paediatrics at the University of Melbourne, Australia. With her team, she is interested in understanding the molecular and cellular bases of neurodevelopmental disorders by using *in vitro* 3D stem cell organoid models that resemble the developing human brain. Prior to joining MCRI, she was a senior scientist in the Stanley Center for psychiatric research at the Broad Institute, and an affiliate in the Department of Stem Cell and Regenerative Biology at Harvard University. Her interest in stem cell biology and neurodevelopmental neuroscience began during her postdoctoral training at New York University, and at the National Hospital for Paraplegics, in Spain. She holds a Ph.D. in Human Biology and M.Sci. in Medical Biotechnology from the University of Turin, Italy.



**Giuseppina Tesco MD PhD** is a Professor of Neuroscience at **Tufts University School of Medicine**. Her research focuses on Alzheimer's disease (AD). She has been studying the mechanisms of regulation of both  $\beta$ - and  $\gamma$ -secretase activity, the proteases involved in the generation of the toxic amyloid beta peptide, which accumulates in the brain of AD patients. The goal of her research is to determine the molecular mechanisms leading to Alzheimer's disease and identify therapeutic targets. Before joining Tufts University in 2009 she was a junior Faculty at Harvard Medical School and Massachusetts General Hospital. She holds an MD, PhD in Neuroscience, and residency training in Neurology from the University of Florence, Florence, Italy.



**Tooba Cheema** is Senior Director at **Oncorus Inc.** in Cambridge, leading the translational medicine and biomarker strategy for oncolytic virus immunotherapies. Tooba, has 10 years of experience in immunology/oncology projects in industry, advancing them from early discovery, lead selection through translational medicine and clinical development. Prior to Oncorus, Tooba led the non-clinical pharmacology and translational efforts advancing T cell therapies in combination with antibodies for hematological malignancies and solid tumors at Unum Therapeutics through submission of multiple successful First in Human Investigational New Drug Applications (IND). At Momenta Pharmaceuticals, she contributed to the non-clinical biological characterization of biologics and biosimilars for autoimmune and oncology indications.

Tooba has a Ph.D. in Pharmacology from the University of Michigan-Ann Arbor and B.Sc in Biochemistry from Tufts University. She received her post-doctoral training at Massachusetts General Hospital under the fellowship from the American Brain Tumor Association.



**Adnan Abu-Yousif** is a Sr. Director in the Oncology Drug Discovery Unit at Takeda where he leads the cold-to-hot biology team. This part of the portfolio is comprised of approaches that aim to transform what is known as a “cold” or poor, immune response at the tumor interface to one that is “hot,” or fully ignited. He has taken on increasing responsibilities in his seven years at Takeda ranging from leading projects, people, and portfolio. His team focuses on partnership both internally and externally to bring novel medicines to the clinic with a biotech mindset. Prior to joining Takeda Adnan worked at Merrimack Pharmaceuticals where he supported preclinical development of MM-131, a bi-specific antibody that inhibits c-MET signaling including lead selection, optimization, and diagnostic strategy implementation. He has a Ph.D. in Pharmacology, Toxicology and Experimental Therapeutics from the University of Kansas and enjoyed an academic postdoc at Massachusetts General Hospital.

When he's not working, Adnan loves being outside and taking on whatever activities make sense with the season with his wife and two kids.



**Dr. Lorena Pantano** earned a PhD in computational biology in 2011 from the Center of Genomic Regulation, in Barcelona (Spain). Lorena's research at **TH Chan Harvard School** and multiple biotechs in Cambridge, MA for the last 11 years has focused on genomic regulation and data integration. Lorena has experience in biological data analysis using the most well-established tools and has been contributing to the development of novel algorithms to improve the quantification and visualization of genomic data. Lorena approaches scientific challenges with passion and believes that a collaboration and not an individual alone can successfully conquer them.



## **Madelyn Myers**

As a Team Lead in Professional Services at Benchling, Madelyn leads a global team responsible for delivering complex implementation projects on the East Coast and in EMEA. Madelyn works closely with client scientists to digitize their laboratory data and help them to better collaborate, getting those early innovations to market faster. Prior to joining Benchling, Madelyn was a protein scientist in industry working primarily at Juno Therapeutics in the immunotherapy field. She also was the first hire at TScan Therapeutics and was an integral part of the scientific and operational launch of the company. Madelyn holds a M.S. in Biotechnology from Brandeis University, and a B.S. in Animal Science and Biotechnology from the University of Missouri.



**Keerthi Shetty, Ph.D.** is currently Associate Director of Program Management at **Intellia Therapeutics**, a biotech company in Cambridge, MA, developing therapies using the CRISPR gene editing system. Before Intellia she was Senior Manager, Strategic Initiatives of the Center for Personal Cancer Vaccines as well as the Translational Immunogenomics Lab at Dana-Farber Cancer Institute in Boston, where she also served as a Business Development Fellow. Right after obtaining her degree from Yale, she was a Hellman Fellow in Science and Technology Policy at the American Academy of Arts and Sciences in Cambridge, MA, where she worked with senior scientists and policy experts to better understand the public return on investment in scientific research.



**Helen Josephine** is an accomplished scientist in the field of cancer metabolism and protein homeostasis. She has delivered results which have led to Lead Op milestones for two projects and one project moving to the clinic. She is a team player who believes in collaboration and that no single person can accomplish what we can accomplish as a team. Helen also has experience in the field of Enzymology, Cancer cell biology, Protein biochemistry and antibiotic resistance.

She has managed CROs across different countries and delivered results which helped programs reach their milestones. Helen has also managed academic collaborations, delivering results to steer program forward.



**Jennifer E. Carinci, EdD, PMP**, brings extensive experience launching new research initiatives and leading diverse partnerships, in addressing gaps in the field and ultimately improving stakeholder outcomes, to her work as ERVA executive director.

She most recently served as program director for STEM Education Research at the American Association for the Advancement of Science (AAAS), leading efforts to improve instruction and broaden participation. As principal investigator (PI) of National Science Foundation (NSF) grants, Carinci spearheaded the development of two new communities designed to form connections across people and ideas within and outside of NSF-funded PIs. Advancing Research & Innovation in the STEM Education of Preservice Teachers in High-Need School Districts (ARISE), debuted in 2018 with Robert Noyce Teacher Scholarship funding, to provide resources and a forum to foster research and evidence-based innovation in STEM teacher education; and through the Improving Undergraduate STEM Education (IUSE) program, she led the creation of the AAAS-IUSE Initiative in 2020 to support the greater undergraduate STEM education community by disseminating research and knowledge about STEM learning, equity, and institutional transformation. Her project portfolio also included managing the L'Oréal USA Fellowships for Women in Science program – a national award that annually recognizes five U.S.-based women researchers at the beginning of their scientific careers – and advising on the AAAS IF/THEN Ambassadors program, an initiative to create a culture shift around the perceptions of women in STEM careers who serve as high-profile role models for middle school girls.

Previously, Carinci was the inaugural director of research, innovation, and data strategy at the Council for the Accreditation of Educator Preparation (CAEP). Given the newness of both the position and the organization, her role involved shaping and implementing an ambitious agenda to advance educator preparation. Prior to CAEP, Carinci trained as an Institute of Education Sciences (IES) Pre-Doctoral Training Fellow with a background as a middle and high school art teacher in Baltimore City.

She has served as a board member of multiple higher education and K-12 organizations, as well as reviewing for NSF, the U.S. Department of Education, the American Educational Research Association (AERA), and the District of Columbia Office of the State Superintendent of Education (OSSE). She is the recipient of the NSF STEM for All Video Showcase award and was named the Maryland Art Education Association's New Middle School Art Teacher of the Year as well as a Fulbright Teacher Scholar in Greece. She served as the program chair of the Academic Audit Research in Teacher Education SIG and is a past member of the AERA Council. Carinci holds a bachelor in fine arts degree from Maryland Institute College of Art (MICA), as well as a master's degree in education and a doctorate in teacher development and leadership from Johns Hopkins University.



**Dr. Rachel Harding** is a Research Associate based at the Structural Genomics Consortium (SGC) at the University of Toronto, Canada. Dr. Harding leads the Huntington's disease research team at the SGC, the research focus of which is to understand the structure and function of the huntingtin protein mutated in this disease. Dr Harding completed her undergraduate and PhD studies at the University of Oxford before moving to the University of Toronto to complete her postdoctoral training in the lab of Prof. Cheryl Arrowsmith. Dr Harding is a passionate advocate of open science practises, and has shared 500+ protein and plasmid samples from her Huntington's disease toolkit with labs around the world, works on the steering committee of the Canadian Open Neuroscience Platform as well as ensuring all of her publications and data are available under open licenses.



**Susanna Bachle** holds a PhD in Medical Science with a focus on Human Immunology and Virology. She has lived and worked in Germany, Sweden and the US. Recent positions include Business Development for Olink Proteomics, a protein biomarker biotech company and team lead for Scientific Outreach and Strategic Partnerships with Addgene before joining **Sanofi** as Medical Science Liaison for Vaccines in 2020. Her role focuses on scientific exchange with experts and education covering all vaccine-preventable diseases in the US.



**Yuri Klyachkin, PhD.**

**Yuri Klyachkin, PhD** is a Medical Director at **Amgen** supporting the dermatology and rheumatology pipeline and medical activities in the US. Prior to joining Amgen, he spent 5 years at Celgene and Bristol Meyers-Squibb as a medical science liaison supporting assets in inflammation. He earned his PhD in immunology from the University of Kentucky followed by a post-doctorate fellowship in stem cell signaling. Yuri is actively involved in the Cheeky Scientist Association helping other PhDs discover their careers and passions in the private sector. In his spare time he enjoys relaxing with his family as well as playing tennis and poker.



**Sohini Mazumdar, PhD.**

Mom of 1 | Business Development Professional | Connector

Sohini leads business development activities at Agios Pharmaceuticals, a company focused on finding cures for genetically defined diseases grounded in cellular metabolism. In this role, she dons both scientific and business hats to identify and execute on the most strategically suited assets in addition to identifying opportunities that maximize the value of the Agios portfolio. She is a scientist by training (PhD, Genetics, Tufts University School of Medicine) and went on to pursue business and early commercialization strategy at Clarion Healthcare, a boutique strategy consulting firm in Boston.

Following her experience at Clarion, Sohini further explored the art and science of investments in the early/preclinical space at Partners Healthcare Innovation. Sohini has worked for over 10 years to mentor young scientists and build the STEM community through involvement in various nonprofit organizations including MASS AWIS, WEST and HBA. She is a representative of the Agios diversity, equity, and inclusion (DEI) Council and champions causes and activities that foster and build cultural connections at Agios. Sohini enjoys traveling around the world and exploring new cuisines with her husband and curious minded four-year-old. She also dabbles in experiments with acrylic and oil paints, photography and aspires one day to write a YA novel.



## Follow Us



@MASSAWIS



MASS AWIS



Massachusetts



AWIS

[bit.ly/2GylKjO](http://bit.ly/2GylKjO)